Seventeen pharmaceutical companies were listed on the "Fortune" China 500, led by Sinopharm; Heavy Medicine, CSPC, Hengrui have made great progress; Shanghai Pharmaceuticals, Ruikang, Baiyunshan...

On the evening of July 20th, Fortune Plus APP just released the 2021 Fortune China 500 list, taking into account the performance and achievements of the world's largest listed Chinese company in the past year
.

Last year, China's GDP exceeded 100 trillion yuan, and the total income of the 500 listed companies on the list this year reached 53 trillion yuan, more than half of China's GDP that year
.

Among them, pharmaceutical companies performed well, with 17 companies on the list.
Sinopharm, Shanghai Pharmaceutical Group Co.
, Ltd.
, and China Resources Pharmaceutical Group Co.
, Ltd.
ranked in the pharmaceutical category with revenues of 456.
4 billion yuan, 191.
9 billion yuan, and 178.
2 billion yuan, respectively.
Among the top three companies, and among the top 100 companies, Jointown Pharmaceutical Group Co.
, Ltd.
also ranks among the top 100 with a revenue of 110.
86 billion yuan
.

2020 Fortune 500 Chinese Pharmaceutical Companies Ranking List

Six companies have risen in rankings, and Sinopec, CSPC, and Hengrui Pharmaceutical have made great progress

According to Yaozhi.

Among them, China Heavy Pharmaceutical Holdings Co.
, Ltd.
has increased by 39 in 2020, making it the company with the most progress.
According to the 2020 financial report of China Heavy Pharmaceutical Holdings Co.
, Ltd.
, operating income in 2020 is 45.
22 billion yuan, a year-on-year increase of 33.
61%; net profit attributable to the parent 884 million yuan, an increase of 12.
22% year-on-year
.

The second is CSPC.
It is reported that this is the third time that CSPC has entered the list after entering the list in 2019.
It ranks 397 with a revenue of 24.
942 billion yuan, which is 21 places higher than in 2020.
It has accumulated rankings in the past three years.
Increased by 65 positions
.

Hengrui Pharmaceuticals, the “first brother” of domestic pharmaceutical R&D, also performed well, rising by 20 places; according to the financial report, Hengrui Pharmaceuticals achieved operating income of 27.
735 billion yuan in 2020, a year-on-year increase of 19.
09%; net profit was 6.
328 billion yuan, A year-on-year increase of 18.
78%
.

The ranking of 10 companies fell, Tasly Pharmaceuticals fell out of the list

In addition, there are 10 companies that have shown varying degrees of decline in rankings, namely, Shanghai Pharmaceuticals, China Resources Pharmaceuticals, Guangzhou Baiyunshan, Shenzhen Neptunus Biopharmaceuticals, Nanjing Pharmaceuticals, China Pharmaceutical Health Industry, East China Pharmaceuticals, Ruikang Pharmaceuticals, China Biopharmaceuticals, and Human Resources.
Fu Medicine
.

Among them, the ranking of Ruikang Pharmaceutical dropped the most from 275 in 2020 to 379; it dropped 104 places; it is reported that this is another sharp decline in the ranking of Ruikang Pharmaceutical after 2020 (from 261 in 2020) To 275)
.